WP
TEVA icon

Woodline Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Woodline Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.3M Buy
1,189,584
+25,721
+2% +$857K 0.12% 219
2026
Q1 		$35.1M Buy
1,163,863
+29,867
+3% +$961K 0.13% 207
2025
Q4 		$35.4M Buy
1,133,996
+408,910
+56% +$10.1M 0.14% 192
2025
Q3 		$14.6M Buy
725,086
+176
+0% +$3.09K 0.07% 344
2025
Q2 		$12.1M Sell
724,910
-319,700
-31% -$5.16M 0.06% 382
2025
Q1 		$16.1M Hold
1,044,610
– – 0.1% 264
2024
Q4 		$23M Sell
1,044,610
-2,943
-0.3% -$53.5K 0.16% 187
2024
Q3 		$18.9M Hold
1,047,553
– – 0.16% 199
2024
Q2 		$17M Hold
1,047,553
– – 0.16% 184
2024
Q1 		$14.8M Hold
1,047,553
– – 0.14% 209
2023
Q4 		$10.9M Buy
+1,047,553
New +$9.78M 0.12% 220
2022
Q3 		– Sell
-2,040,175
Closed -$15.3M – 817
2022
Q2 		$15.3M Buy
+2,040,175
New +$17.8M 0.24% 132

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Woodline Partners's TEVA Position: Q2 2026 in Review

Woodline Partners increased its Teva Pharmaceuticals (TEVA) stake by 2.2% in Q2 2026, buying an estimated $857K and bringing the position to 1,189,584 shares worth $40.3M. The position accounts for 0.12% of the portfolio, ranked #219.

Woodline Partners first reported a position in TEVA in Q2 2022 and has held it in 12 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Woodline Partners held 1,189,584 shares of Teva Pharmaceuticals worth $40.3M as of Q2 2026.
  • Woodline Partners bought 25,721 Teva Pharmaceuticals shares in Q2 2026, an estimated $857K.
  • Teva Pharmaceuticals made up 0.12% of Woodline Partners's portfolio in Q2 2026, its #219 holding.
  • Woodline Partners first reported a position in Teva Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.